T5O — bioXXmed AG Income Statement
0.000.00%
Last trade - 00:00
- €2.85m
- €1.77m
- €0.01m
- 27
- 30
- 16
- 13
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | — | — | — | — | GAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.036 | 0.036 | 0.045 | 0.012 |
Cost of Revenue | |||||
Gross Profit | — | 0.036 | — | — | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.22 | 1.21 | 1.87 | 1.57 | 0.835 |
Operating Profit | -1.22 | -1.17 | -1.84 | -1.53 | -0.823 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.42 | -1.27 | -1.84 | -4.02 | -0.83 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.42 | -1.27 | -1.84 | -4.06 | -0.83 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.42 | -1.27 | -1.84 | -4.06 | -0.83 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.42 | -1.27 | -1.84 | -4.06 | -0.83 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.514 | -0.338 | -0.443 | -0.978 | -0.162 |
Dividends per Share |